Early Breast Cancer

[1]  R. Baynes,et al.  High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? , 2001, Seminars in oncology.

[2]  P. Ang,et al.  Genetic susceptibility for breast cancer--risk assessment and counseling. , 2001, Seminars in oncology.

[3]  R. Wooster,et al.  Breast cancer genetics: What we know and what we need , 2001, Nature Medicine.

[4]  D. Hayes,et al.  When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Piccart,et al.  HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients? , 2000, European journal of cancer.

[6]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[7]  Terry L. Smith,et al.  Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.

[8]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[9]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[10]  J. Peterse,et al.  Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.

[11]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[12]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[13]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[14]  T. Yeatman,et al.  Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. , 1998, Annals of surgery.

[15]  G. Hortobagyi,et al.  Update on endocrine therapy for breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  K. Zedeler,et al.  Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy , 1997 .

[17]  N. Le,et al.  Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. , 1997, The New England journal of medicine.

[18]  M. P. Moore,et al.  Axillary lymphadenectomy: A diagnostic and therapeutic procedure , 1997, Journal of surgical oncology.

[19]  I. Smith.  Patient benefits from new treatment options and schedules for breast cancer. , 1997, Seminars in oncology.

[20]  A. Seidman,et al.  Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. , 1997, Seminars in oncology.

[21]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A E Giuliano,et al.  Sentinel lymphadenectomy in breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Lund,et al.  Physical activity and the risk of breast cancer. , 1997, The New England journal of medicine.

[24]  M. Piccart,et al.  Conclusions: future strategies in the treatment of breast cancer. , 1997, Seminars in oncology.

[25]  J. Forbes.  The incidence of breast cancer: the global burden, public health considerations. , 1997, Seminars in oncology.

[26]  V. Jordan,et al.  Risks and benefits of tamoxifen therapy. , 1997, Oncology.

[27]  J. Olsen,et al.  Induced abortion and the risk of breast cancer. , 1997, The New England journal of medicine.

[28]  T. Yeatman,et al.  Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. , 1996, JAMA.

[29]  C. Meltzer,et al.  MR imaging of the meninges. Part II. Neoplastic disease. , 1996, Radiology.

[30]  J. Freudenheim,et al.  Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. , 1996, JAMA.

[31]  O. Olopade.  Genetics in clinical cancer care--the future is now. , 1996, The New England journal of medicine.

[32]  R. Goldschmidt,et al.  Lobular carcinoma in situ of the breast. , 1996, Seminars in surgical oncology.

[33]  N. Ellerbroek.  Sequencing of chemotherapy and radiation therapy in the treatment of early breast cancer: the devil is in the details. , 1996, Radiology.

[34]  R. Gelber,et al.  Endocrine therapies of breast cancer. , 1996, Seminars in oncology.

[35]  C. Redmond,et al.  Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Recht,et al.  The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. , 1996, The New England journal of medicine.

[37]  F. Visco.  Commentary on the ASCO Statement on Genetic Testing for Cancer Susceptibility , 1996 .

[38]  K. Kerlikowske,et al.  Incidence of and treatment for ductal carcinoma in situ of the breast. , 1996, JAMA.

[39]  F. Speizer,et al.  Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. , 1996, The New England journal of medicine.

[40]  Anthony Howell,et al.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. , 1995, The New England journal of medicine.

[41]  Mike Clarke,et al.  EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS , 1995 .

[42]  Ronin,et al.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. , 1995, The New England journal of medicine.

[43]  G. Bonadonna,et al.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.

[44]  I. Ellis,et al.  Histologic grading of breast cancer. Let's do it. , 1995, American journal of clinical pathology.

[45]  J. Foekens,et al.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[47]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[48]  M. Thangaraju,et al.  Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer , 1994, Cancer.

[49]  R. Bast,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  W. Willett,et al.  Breast cancer (2). , 1992, The New England journal of medicine.

[51]  W. Willett,et al.  Breast cancer (1) , 1992, The New England journal of medicine.

[52]  R. Weichselbaum,et al.  Prognostic indicators in node-negative early stage breast cancer. , 1992, The American journal of medicine.

[53]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[54]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[55]  R. Gelber,et al.  Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Anna L. Brown,et al.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[58]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[59]  S Hellman,et al.  Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  W. Willett,et al.  Moderate alcohol consumption and the risk of breast cancer. , 1987, The New England journal of medicine.

[61]  C. Redmond,et al.  Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  G. Bonadonna,et al.  Adjuvant CMF chemotherapy in operable breast cancer: Ten years later , 1985, World Journal of Surgery.

[63]  S D Stellman,et al.  A different perspective on breast cancer risk factors: Some implications of the nonattributable risk , 1982, CA: a cancer journal for clinicians.

[64]  A. Luini,et al.  Comparing Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiotherapy in Patients with Small Cancers of the Breast , 1981 .

[65]  R. W. Crichlow.  Breast cancer in men. , 1974, Seminars in oncology.

[66]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[67]  B. Fisher,et al.  Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials , 2004, World Journal of Surgery.

[68]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[69]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[70]  M. Zelen,et al.  Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  W. Donegan.  Tumor‐related prognostic factors for breast cancer , 1997, CA: a cancer journal for clinicians.

[72]  M. Skolnick,et al.  Statement of the American Society of Clinical Oncology : Genetic testing for cancer susceptibility. Commentaries , 1996 .